Treatment of chronic hepatitis C infection: Update of the recommendations from scientific leader's meeting-28th july 2011-Tehran, IR Iran

Hepatitis Monthly

Volumn 11, Issue 9, 2011, Pages 703-713

  Alavian, Seyed Moayed ^a   Lankarani, Kamran Bagheri ^b   Aalaei Andabili, Seyed Hossein ^a   Pouryasin, Ali ^c   Daryani, Nasser Ebrahimi ^d   Toosi, Mohsen Nassiri ^d   Malekzadeh, Reza ^e   Zali, Mohammad Reza ^f   Mohraz, Mino ^g  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis C; Iran; Public health; Therapy

Indexed keywords

ALFUZOSIN; BOCEPREVIR; CARBAMAZEPINE; CISAPRIDE; DIHYDROERGOTAMINE; DROSPIRENONE; ERGOMETRINE; ERGOTAMINE; ERYTHROPOIETIN; INTERFERON; INTERLEUKIN 28; LURASIDONE; METHYLERGOMETRINE; MEVINOLIN; MIDAZOLAM; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PROTEINASE INHIBITOR; RIBAVIRIN; RIFAMPICIN; SIMVASTATIN; TADALAFIL; TRIAZOLAM; VIRUS RNA;

ANEMIA; ANTIVIRAL THERAPY; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; GENOTYPE; HEALTH CARE POLICY; HEPATITIS C; HUMAN; IRAN; NEUTROPENIA; PATIENT CARE PLANNING; PRACTICE GUIDELINE; REVIEW; SYMPOSIUM; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS LOAD;

EID: 80053633266     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/kowsar.1735143X.501     Document Type: Review

References (67)

1. Taylor MW, Tsukahara T, McClintick JN, Edenberg HJ, Kwo P. Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med. 2008; 6:66.
2. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med. 2005; 8:84-90.
3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 1317): 2436-41.
4. Umar M, Bushra H, Ahmad M, Khurram M, Usman S, Arif M, et al. Hepatitis C in Pakistan: A Review of Avaiable Data. Hepat Mon. 2010; 10(3):205-14.
5. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9):558-67.
6. Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol. 2003; 38 (Suppl 1):S104-18.
7. Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol. 2000; 12(6):667-78.
8. Wyles DL. Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection. Top HIV Med. 2010; 18(4):132-6.
9. Ahmadipour MH AS, Amini S, Azadmanesh K. Hepatitis C Virus Genotypes. Hepat Mon. 2005; 5(3):6.
10. Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int. 2010; 30(8):1173-80.
11. Kobayashi K, Ooba S, Saeki R, Minouchi K, Kaneko S, Inagaki Y, et al. Clinical pathoepidemiology of hepatocellular carcinoma in Japan. Princess Takamatsu Symp. 1995; 25:67-74.
12. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 (Suppl 1):74-81.
13. Arens M. Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. J Clin Virol. 2001; 22(1):11-29.
14. Preston FE, Jarvis LM, Makris M, Philp L, Underwood JC, Ludlam CA, et al. Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease. Blood. 1995; 85(5):1259-62.
15. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: A case-control study. J Gastroenterol Hepatol. 2002; (1710): 1092-7.
16. Alavian SM, Kafaee J, Yektaparast B, Hajarizadeh B, Doroudi T. The efficacy of blood donor screening in reducing the incidence of hepatitis C virus infection among thalassemic patients in Iran. Transfusion Today. 2002; 53:3-4.
17. Alavian SM, Mahdavi-Mazdeh M, Bagheri-Lankarani K. Hepatitis B and C in dialysis units in Iran, Changing the epidemiology. Hemodial Int. 2008; 12:378-82.
18. Alavian SM, Ahmadzad Asl M, Lankarani KB, Shahbabaie MA, Bahrami Ahmadi A, Kabir A. Hepatitis C Infection in the General Population of Iran: A Systematic Review. Hepat Mon. 2009; 9(3):211-23.
19. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first populationbased study from Iran. Int J Infect Dis. 2010; 14 (Suppl 3):e113-6.
20. Amini S, Farahani Majd Abadi M, Alavian SM, Joulaie M, Ahmadipour MH. Distribution of Hepatitis C Virus Genotypes in Iran: A Population-Based Study. Hepat Mon. 2009; 9(2):95-102.
21. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: A case-control study. J Gastroenterol Hepatol. 2002; 1710): 1092-7.
22. Friedman SL. Evaluation of fibrosis and hepatitis C. Am J Med. 1999; 107(6B):27S-30S.
23. Seeff LB. Natural history of hepatitis C. Hepatology. 1997; 26(3 Suppl 1):21S-8S.
24. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999; 29(4):1215-9.
25. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349(9055):825-32.
26. Pol S, Fontaine H, Carnot F, Zylberberg H, Berthelot P, Brechot C, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol. 1998; 29(1):12-9.
27. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology. 1998; 27(6):1717-22.
28. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology. 1994; 19(1):13-8.
29. Davis GL. Hepatitis C virus genotypes and quasispecies. Am J Med. 1999; 107(6B):21S-6S.
30. Cropley I, Main J. Hepatitis C virus infection: co-infection with HIV and HBV. Baillieres Best Pract Res Clin Gastroenterol. 2000; 14(2):265-75.
31. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999; 30(4):1054-8.
32. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis. 1999; 179(5):1254-8.
33. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997; 26(1):1-5.
34. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet. 1997; 350(9089):1425-31.
35. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001; 34(4 Pt 1):809-16.
36. Bird SM, Goldberg DJ, Hutchinson SJ. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 2: Preliminary UK estimates of prevalent injection-related hepatitis C carriers, and derivation of progression rates to liver cirrhosis by gender and age at hepatitis C virus infection. J Epidemiol Biostat. 2001; 6(3):267-77; discussion 79-85.
37. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol. 2005; 311): 1150-9.
38. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology. 2005; 42(3):711-23.
39. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002; 122(5):1303-13.
40. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009; 50(2):407-13.
41. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010; 8(2):192-9.
42. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009; 96(9):975-81.
43. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care. 2005; 11(10 Suppl):S286-95; quiz S307-11.
44. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361(6):580-93.
45. Gevers TJ, Slavenburg S, van Oijen MG, Drenth JP. Treatment extension benefits HCV genotype 1 patients without rapid virological response: a systematic review. Neth J Med. 2011; 69(5):216-21.
46. Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Imanaka K, Yamada A, et al. The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol. 2011; 46(7):944-52.
47. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011; 55(1):69-75.
48. Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, et al. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011; 106(3):452-8.
49. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008; 47(6):1884-93.
50. Slavenburg S, Weggelaar I, van Oijen MG, Drenth JP. Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. Antivir Ther. 2009; 14(8):1139-48.
51. Alavian SM, Tabatabaei SV, Behnava B, Mahboobi N. Optimal Duration of Anti-HCV Treatment in Genotype-1 Slow Responders: A Meta-Analysis. Hepat Mon. 2011; 11(8):[Epub ahead of print].
52. Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol. 2010; 52(1):25-31.
53. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl j Med. 2011; 36413): 1207-17.
54. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2011; 8(5):257-64.
55. Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother. 2006; 50(3):1013-20.
56. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009; 50(6):1709-18.
57. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010; 376(9742):705-16.
58. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 36413): 1195-206.
59. Nelson DR. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients. Liver Int. 2011; 31 (Suppl 1):53-7.
60. Boceprevir FDA approved Full Prescribing Information, May 13, 2011.
61. Jensen DM. A new era of hepatitis C therapy begins. N Engl J Med. 2011; 36413): 1272-4.
62. Background Material for Boceprevir Advisory Committee Division of Antiviral Products (DAVP) April 27.
63. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008; 198(6):800-7.
64. Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother. 2004; 4812): 4784-92.
65. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010; 139(1):120-9 e18.
66. Boceprevir Facts and Comparisons. www.Drugs.com. 6 July,2011.
67. Qureshi S, Batool U, Iqbal M, Qureshi O, Kaleem R, Aziz H, et al. Response rates to standard interferon treatment in HCV genotype 3a. J Ayub Med Coll Abbottabad. 2009; 21(4):10-4.